SXTP Stock Forecast: 60 Degrees Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.47
−6.36% on the day

The median 12-month analyst price target for 60 Degrees Pharmaceuticals, Inc. is $3.7. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 36 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$2.1M
Ticker Nerd rank
36/ 100
Median analyst target
$3.70
Analysts covering
2
Revenue$208K+106.0% y/y
Operating income−$2.3M
Net income−$2.3M
Free cash flow−$2.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.6%
1M
−49.2%
YTD
−77.0%
1Y
−88.4%
From 52W high
−91.0%
From 52W low
0.0%
$0.47
$5.20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores 60 Degrees Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
36/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
75
Accruals
70
Value
38
Quality
35
Growth
29
Volatility
23
Issuance
12
Momentum
5

Revisions (75): Analysts have, on balance, been raising their forecasts.

Momentum (5): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SXTP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SXTP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00Jan 26Apr 26Jul 26Oct 26SXTPHigh $3.70Median $3.70Low $3.70

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
1
Buy
1
Hold
0
Sell
$3.70
Low
$3.70
Median
$3.70
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 May 2026Ascendiant CapitalMaintainsBuy$4.20 → $3.70
20 May 2026HC Wainwright & Co.DowngradeNeutral—
9 Apr 2026Ascendiant CapitalMaintainsBuy—
27 Jan 2026HC Wainwright & Co.MaintainsBuy—
28 Nov 2025Ascendiant CapitalMaintainsBuy—
14 Nov 2025HC Wainwright & Co.AssumesBuy$6.00
3 Sept 2025Ascendiant CapitalMaintainsBuy—
2 June 2025Ascendiant CapitalMaintainsBuy—
28 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
25 Feb 2025HC Wainwright & Co.ReiteratesNeutral—
10 Jan 2025HC Wainwright & Co.ReiteratesNeutral—
23 Dec 2024HC Wainwright & Co.ReiteratesNeutral—
11 Dec 2024HC Wainwright & Co.ReiteratesNeutral—
15 Nov 2024HC Wainwright & Co.ReiteratesNeutral—
13 Sept 2024HC Wainwright & Co.ReiteratesNeutral—
15 Aug 2024HC Wainwright & Co.ReiteratesNeutral—
6 June 2024HC Wainwright & Co.ReiteratesNeutral—
3 Apr 2024HC Wainwright & Co.ReiteratesNeutral—
20 Oct 2023HC Wainwright & Co.InitiatesNeutral—
2 Oct 2023Ascendiant CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SXTP.

Market Radar

This page is one stock. Monday covers all of them.

SXTP appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SXTP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, 60 Degrees Pharmaceuticals, Inc. returned −88.4% against +6.9% for the S&P 500, dividends included.

SXTP vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120140Jan 26Apr 26Jul 26Oct 26SXTPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SXTP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
2.3×

Cheaper than 45% of US stocks

Price / book
0.5×

Cheaper than 86% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
27.3%

Higher than 30% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−327.4%

Higher than 4% of US stocks

Return on assets
−112.6%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • 60 Degrees Pharmaceuticals, Inc. has a market value of $2.1M and an enterprise value of $10.4M.

  • Revenue in the twelve months to 30 June 2026: $1.1M. The latest quarter grew 106.0% year on year.

  • Net income over the same four quarters: −$8.1M, a −730.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$9.1M, after $81K of capital spending.

  • Shares outstanding: 2.7M.

  • 60 Degrees Pharmaceuticals, Inc. employs 3 people — $370K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

SXTP and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SXTP60 Degrees Pharmaceuticals, Inc.$2.1M36
KAPAKairos Pharma Ltd.$2.0M35
LABTLakewood-Amedex Biotherapeutics, Inc.$2.2M17
ERNAErnexa Therapeutics, Inc.$2.2M18
DCOYDecoy Therapeutics, Inc.$2.0M15
PMCBPharmaCyte Biotech, Inc.$2.2M25
GNPXGenprex, Inc.$1.9M10

Take a look at SXTP’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own 60 Degrees Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about SXTP

What is the SXTP stock price forecast for 2026-2027?

The median 12-month analyst price target for 60 Degrees Pharmaceuticals, Inc. is $3.7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SXTP stock a buy right now?

Of the 2 analysts covering 60 Degrees Pharmaceuticals, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks 60 Degrees Pharmaceuticals, Inc. 36 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SXTP?

As at 21 Nov 2026, 60 Degrees Pharmaceuticals, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (75 of 100).

Will SXTP stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $3.7, and Ticker Nerd's factor model ranks 60 Degrees Pharmaceuticals, Inc. 36 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SXTP stock forecast for 2030?

No analyst covering 60 Degrees Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SXTP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.7 to $3.7 over the next 12 months.

How has SXTP stock performed over the past year?

60 Degrees Pharmaceuticals, Inc. returned -88.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does 60 Degrees Pharmaceuticals, Inc. do?

60 Degrees Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing medicines for the prevention and treatment of infectious diseases. Its commercial portfolio centers on Arakoda, a malaria prevention therapy, while its broader pipeline includes tafenoquine-based programs and other candidates being studied for vector-borne, fungal, and viral infections.

Company

About 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing medicines for the prevention and treatment of infectious diseases. Its commercial portfolio centers on Arakoda, a malaria prevention therapy, while its broader pipeline includes tafenoquine-based programs and other candidates being studied for vector-borne, fungal, and viral infections. The company works across areas such as malaria, babesiosis, respiratory infections, and dengue, reflecting a research strategy aimed at diseases with significant unmet medical need. 60 Degrees Pharmaceuticals Inc. serves as a niche biotechnology player in the healthcare market, combining product commercialization with ongoing clinical development. Headquartered in Washington, D.C., the company also maintains operations linked to research and collaboration in Australia.

CEO Dr. Geoffrey Stuart Dow Ph.D. · 3 employees · United States · https://www.60degreespharma.com